Interactions of pluronic block copolymers on P-gp efflux activity: Experience with HIV-1 protease inhibitors

Journal of Pharmaceutical Sciences

Volumn 97, Issue 12, 2008, Pages 5421-5433

  Shaik, Naveed ^a   Pan, Guoyu ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

ATPase P glycoprotein; Blood brain barrier; Efflux pumps; HIV 1 protease inhibitors; Pluronics; Polymers

Indexed keywords

ADENOSINE TRIPHOSPHATASE; COPOLYMER; GLYCOPROTEIN P; NELFINAVIR; PLURONIC F 88; PLURONIC P 85; POLOXAMER; PROTEINASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG TRANSPORT; ENZYME ASSAY; GENE EXPRESSION REGULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; PROTEINASE INHIBITION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 57349147165     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21372     Document Type: Article

References (55)

1. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D. 2007. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids 21:215-223.
2. van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M. 2007. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis 195:399-409.
3. Ances BM, Ellis RJ. 2007. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 27:86-92.
4. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. 2002. Differences in the detection of three HIV-1 protease inhibitors in nonblood compartments: Clinical correlations. HIV Clin Trials 3:27-35.
5. Kravcik S, Gallicano K, Roth V, Cassol S, Hawley-Foss N, Badley A, Cameron DW. 1999. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 21:371-375.
6. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. 2004. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 78:10133-10148.
7. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
8. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
9. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
10. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55:3-29.
11. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
12. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806-813.
13. Ronaldson PT, Lee G, Dallas S, Bendayan R. 2004. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm Res 21: 811-818.
14. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206-1212.
15. Kaddoumi A, Choi SU, Kinman L, Whittington D, Tsai CC, Ho RJ, Anderson BD, Unadkat JD. 2007. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos 35:1459-1462.
16. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. 2005. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 22:1259-1268.
17. Jorajuria S, Dereuddre-Bosquet N, Becher F, Martin S, Porcheray F, Garrigues A, Mabondzo A, Benech H, Grassi J, Orlowski S, Dormont D, Clayette P. 2004. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther 9:519-528.
18. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF. 2000. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 28:1058-1062.
19. Perloff MD, von Moltke LL, Fahey JM, Greenblatt DJ. 2007. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 59:947-953.
20. Salama NN, Kelly EJ, Bui T, Ho RJ. 2005. The impact of pharmacologic and genetic knockout of Pglycoprotein on nelfinavir levels in the brain and other tissues in mice. J Pharm Sci 94:1216-1225.
21. Constantinides PP, Wasan KM. 2007. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: In vitro/in vivo case studies. J Pharm Sci 96:235-248.
22. Dintaman JM, Silverman JA. 1999. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550-1556.
23. Varma MV, Panchagnula R. 2005. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25:445-453.
24. Johnson BM, Charman WN, Porter CJ. 2002. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharm Sci 4:E40.
25. Katneni K, Charman SA, Porter CJ. 2007. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: Delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J Pharm Sci 96:280-293.
26. Zhang H, Yao M, Morrison RA, Chong S. 2003. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 26:768-772.
27. Batrakova EV, Li S, Miller DW, Kabanov AV. 1999. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 16:1366-1372.
28. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. 2001. Pluronic P85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies. J Pharmacol Exp Ther 296:551-557.
29. Zastre J, Jackson J, Burt H. 2004. Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block- Polycaprolactone amphiphilic diblock copolymers. Pharm Res 21:1489-1497.
30. Regev R, Katzir H, Yeheskely-Hayon D, Eytan GD. 2007. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J 274:6204-6214.
31. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. 2001. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 299:483-493.
32. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. 1992. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267:4854-4858.
33. Batrakova EV, Li S, Alakhov VY, Miller DW, Kabanov AV. 2003. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 304:845-854.
34. Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabo K, Muller M, Hose CD, Monks A, Varadi A, Seprodi J, Sarakadi B. 1999. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol 58:571-586.
35. Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV. 2004. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 21:2226-2233.
36. Garrigos M, Mir LM, Orlowski S. 1997. Competitive and non-competitive inhibition of the multidrugresistance-associated P-glycoprotein ATPase - Further experimental evidence for a multisite model. Eur J Biochem 244:664-673.
37. Orlowski S, Selosse MA, Boudon C, Micoud C, Mir LM, Belehradek J, Jr., Garrigos M. 1998. Effects of detergents on P-glycoprotein atpase activity: Differences in perturbations of basal and verapamil-dependent activities. Cancer Biochem Biophys 16:85-110.
38. Zhang Y, Benet LZ. 1998. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res 15:1520-1524.
39. Williams GC, Knipp GT, Sinko PJ. 2003. The effect of cell culture conditions on saquinavir transport through, and interactions with, MDCKII cells overexpressing hM DR1. J Pharm Sci 92:1957-1967.
40. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. 2000. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: Comparison of endpoint and realtime methods. Anal Biochem 285:194-204.
41. Chandler B, Detsika M, Owen A, Evans S, Hartkoorn RC, Cane PA, Back DJ, Khoo SH. 2007. Effect of transporter modulation on the emergence of nelfinavir resistance in vitro. Antivir Ther 12:831-834.
42. Williams GC, Liu A, Knipp G, Sinko PJ. 2002. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 46:3456-3462.
43. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. 2004. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 143:856-864.
44. Batrakova EV, Li S, Alakhov VY, Elmquist WF, Miller DW, Kabanov AV. 2003. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res 20:1581-1590.
45. Park S, Sinko PJ. 2005. P-glycoprotein and mutlidrug resistance- associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 312:1249-1256.
46. Miller DW, Batrakova EV, Kabanov AV. 1999. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res 16:396-401.
47. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, Friedberg T. 2002. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64:1569-1578.
48. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R. 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
49. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. 1992. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248-24252.
50. Hamada A, Miyano H, Watanabe H, Saito H. 2003. Interaction of imatinib mesilate with human Pglycoprotein. J Pharmacol Exp Ther 307:824-828.
51. Videmann B, Tep J, Cavret S, Lecoeur S. 2007. Epithelial transport of deoxynivalenol: Involvement of human P-glycoprotein (ABCB1) and multidrug resistance-associated protein 2 (ABCC2). Food Chem Toxicol 45:1938-1947.
52. Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. 2007. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci 10:319-331.
53. Sriadibhatla S, Yang Z, Gebhart C, Alakhov VY, Kabanov A. 2006. Transcriptional activation of gene expression by pluronic block copolymers in stably and transiently transfected cells. Mol Ther 13:804-813.
54. Yang Z, Zhu J, Sriadibhatla S, Gebhart C, Alakhov V, Kabanov A. 2005. Promoter- and strain-selective enhancement of gene expression in a mouse skeletal muscle by a polymer excipient Pluronic P85. J Control Release 108:496-512.
55. Batrakova EV, Kelly DL, Li S, Li Y, Yang Z, Xiao L, Alakhova DY, Sherman S, Alakhov VY, Kabanov AV. 2006. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85. Mol Pharm 3:113-123.